RESUMO
Abstract Background: The risk of sports-related sudden cardiac arrest after COVID-19 infection can be a serious problem. There is an urgent need for evidence-based criteria to ensure patient safety before resuming exercise. Objective: To estimate the pooled prevalence of acute myocardial injury caused by COVID-19 and to provide an easy-to-use cardiovascular risk assessment toolkit prior to resuming sports activities after COVID-19 infection. Methods: We searched the Medline and Cochrane databases for articles on the prevalence of acute myocardial injury associated with COVID-19 infection. The pooled prevalence of acute myocardial injury was calculated for hospitalized patients treated in different settings (non-intensive care unit [ICU], ICU, overall hospitalization, and non-survivors). Statistical significance was accepted for p values <0.05. We propose a practical flowchart to assess the cardiovascular risk of individuals who recovered from COVID-19 before resuming sports activities. Results: A total of 20 studies (6,573 patients) were included. The overall pooled prevalence of acute myocardial injury in hospitalized patients was 21.7% (95% CI 17.3-26.5%). The non-ICU setting had the lowest prevalence (9.5%, 95% CI 1.5-23.4%), followed by the ICU setting (44.9%, 95% CI 27.7-62.8%), and the cohort of non-survivors (57.7% with 95% CI 38.5-75.7%). We provide an approach to assess cardiovascular risk based on the prevalence of acute myocardial injury in each setting. Conclusions: Acute myocardial injury is frequent and associated with more severe disease and hospital admissions. Cardiac involvement could be a potential trigger for exercise-induced clinical complications after COVID-19 infection. We created a toolkit to assist with clinical decision-making prior to resuming sports activities after COVID-19 infection.
Assuntos
Esportes , Fatores de Risco de Doenças Cardíacas , COVID-19/complicações , Miocardite/complicações , Morte Súbita Cardíaca , Medição de Risco/métodos , Prática Clínica Baseada em Evidências/métodos , AtletasRESUMO
Fundamento: A remodelagem cardíaca depende da intensidade, da duração e do método de treinamento. Objetivo: Avaliar se o treinamento realizado em uma tropa especial portuguesa incrementa a remodelagem cardíaca em uma amostra de jovens que previamente praticavam esporte de competição. Métodos: Estudo prospectivo que incluiu 76 militares candidatos a tropas especiais, 45 dos quais praticavam previamente exercício físico de nível competitivo (> 10 horas por semana). Destes militares atletas, apenas 17 concluíram com sucesso o curso. A avaliação foi realizada com 6 meses de intervalo e incluiu história clínica completa, exame físico, sinais vitais, dados antropométricos e avaliação ecocardiográfica. Considerou-se significância estatística quando p < 0,05, com intervalo de confiança de 95%. Resultados: No final do curso, verificaram-se diminuição da porcentagem de massa gorda (19,1 ± 3,3% vs. 13,1 ± 3,5%; p < 0,01), aumento da porcentagem de massa muscular (41,3 ± 2,1% vs. 44,4 ± 1,8%; p < 0,01), e diminuição da pressão arterial sistólica, diastólica e frequência cardíaca. Em relação à remodelagem cardíaca, verificaram-se aumento do diâmetro diastólico do ventrículo esquerdo (49,7 ± 3,2 mm vs. 52,8 ± 3,4 mm; p < 0,01), aumento tendencial do volume do átrio esquerdo (27,3 ± 4,5 mL/m2 vs. 28,2 ± 4,1 mL/m2; p = 0,07) e aumento da massa do ventrículo esquerdo (93,1 ± 7,7g/m2 vs. 100,2 ± 11,4 g/m2; p < 0,01). As variáveis funcionais também sofreram alterações, com aumento do S' (15 (13-16) cm/s vs. 17 (16-18) cm/s; p < 0,01) e diminuição da fração de ejeção do ventrículo esquerdo (60 ± 6% vs. 54 ± 6%; p < 0,01). Conclusão: O treinamento físico militar intenso provocou remodelagem cardíaca adicional em atletas de nível competitivo, tanto estrutural como funcional
Background: Cardiac remodeling depends on the intensity, duration, and training method. Objective: To evaluate if the training performed in a Portuguese military special operations troop increases cardiac remodeling in a sample of young individuals who previously practiced competitive sports. Methods: A prospective study involving 76 military candidates for military special operations, 45 of whom previously practiced at competitive level (> 10 hours per week). Of these military athletes, only 17 successfully completed the course. The evaluation was performed at 6 months intervals and included a complete clinical history, physical examination, vital signs, anthropometric data and echocardiographic evaluation. Statistical significance was considered when p < 0.05, with a 95% confidence interval. Results: At the end of the course, there was a decrease in the percentage of fat mass (19.1 ± 3.3% vs. 13.1 ± 3.5%; p < 0.01), an increase in the percentage of lean mass (41.3 ± 2.1% vs. 44.4 ± 1.8%; p < 0.01), and decreased systolic and diastolic blood pressure and heart rate. Regarding cardiac remodeling, there was an increase in left ventricular diastolic diameter (49.7 ± 3.2 mm vs. 52.8 ± 3.4 mm; p < 0.01), an increase trend in left atrial volume (27.3 ± 4.5 mL/m2 vs. 28.2 ± 4.1 mL/m2; p = 0.07) and increased left ventricular mass (93.1 ± 7.7 g/m2 vs.100.2 ± 11.4 g/m2 ; p < 0.01). Functional variables also changed, with an increase in S' (15 (13-16) cm/s vs. 17 (16-18) cm/s; p < 0,01) and a decrease in left ventricular ejection fraction (60 ± 6% vs. 54 ± 6%; p < 0.01). Conclusion: Intense military physical training resulted in additional cardiac remodeling in athletes of competitive level, both structural and functional
Assuntos
Humanos , Masculino , Adulto , Exercício Físico , Atletas , Remodelamento Atrial , Militares , Volume Sistólico , Ecocardiografia/métodos , Interpretação Estatística de Dados , Estudos Prospectivos , Função Ventricular , Eletrocardiografia/métodos , Pressão Arterial , Frequência CardíacaRESUMO
FUNDAMENTO: O trastuzumabe (TZB) é um anticorpo monoclonal humanizado recombinante usado no tratamento do câncer de mama HER2-positivo, com reconhecida cardiotoxicidade associada. Os métodos para sua detecção subclínica precoce não estão bem estabelecidos. OBJETIVO: Avaliar a cardiotoxicidade induzida por TZB em pacientes (pts) portadoras de câncer de mama acompanhadas por um período de 3 meses de tratamento. MÉTODOS: Estudo prospectivo de pts consecutivas em tratamento com TZB para câncer de mama HER2-positivo avançado, admitidas entre maio e setembro de 2010. Foram comparados dados clínicos, laboratoriais e ecocardiográficos antes da introdução de TZB e 3 meses após o início do tratamento com a droga. Foram estudadas a deterioração da função sistólica do ventrículo esquerdo (segundo critérios do Comitê de Avaliação e Revisão Cardíaca) e a função diastólica (classificação da Sociedade Americana de Ecocardiografia). RESULTADOS: Estavam disponíveis dados de 51 pacientes, cuja idade média era de 55,4±14,0 anos. Nenhuma paciente apresentou insuficiência cardíaca sintomática no terceiro mês. Não houve diferenças na fração de ejeção do ventrículo esquerdo (FEVE) aos 3 meses (69,3 ± 7,4 contra 67,1 ± 6,5%, p > 0,05), tendo sido observada redução em 57,9% pts (em apenas uma a FEVE foi < 55%). Houve aumento significativo da relação E/e' (3,9 ± 0,8 contra 8,0 ± 1,9, p < 0,001) devido a uma redução da velocidade e' (0,19 ± 0,02 contra 0,10 ± 0,03, p < 0,001). Os demais parâmetros diastólicos permaneceram inalterados. Tanto o volume atrial esquerdo quanto o ventricular esquerdo permaneceram inalterados. Não houve aumento dos níveis de peptídeo natriurético tipo pró-B N-terminal. Durante o período de seguimento, duas pacientes morreram e duas foram internadas, todas por causas não cardiovasculares. CONCLUSÃO: Durante os três primeiros meses de tratamento com TZB, nenhuma das pacientes apresentou insuficiência cardíaca franca ou deterioração significativa da FEVE. Detectou-se redução significativa da relação e/e', porém sem alterações importantes dos parâmetros de carga e da FEVE.
BACKGROUND: Trastuzumab (TZB) is a recombinant humanized monoclonal antibody, used for the treatment of HER2-positive breast cancer, with recognized associated-cardiotoxicity. The methods for its early sub-clinical detection are not well defined. OBJECTIVE: To evaluate TZB-induced cardiotoxicity in patients (pts) with breast cancer followed for a 3-month period of treatment. METHODS: Prospective study of consecutive pts treated with TZB for advanced HER2-positive breast cancer enrolled between May-September/2010. A comparison of clinical, laboratory and echocardiographic data, prior to and at the 3rd month after starting TZB was performed. Left ventricular systolic function deterioration (Cardiac Review and Evaluation Committee criteria) and diastolic function (American Society of Echocardiography classification) were studied. RESULTS: Data were available for 51 women, mean age = 55.4 ± 14.0y. At the 3rd month, no patient had symptomatic heart failure. Left ventricular ejection fraction (LVEF) did not differ at 3 months (69.3 ± 7.4 vs. 67.1 ± 6.5%, p > 0.05), decreasing in 57.9% pts (only one to LVEF < 55%). There was a significant increase in the E/e' ratio (3.9 ± 0.8 vs. 8.0 ± 1.9, p < 0,001) due to an e' velocity reduction (0.19 ± 0.02 vs. 0.10 ± 0.03, p < 0.001). Other diastolic parameters remained unchanged. Both the left atrial and the left ventricular volumes remained unchanged. N-terminal pro-B type natriuretic peptide levels did not increase. During the follow up period two pts died and two were admitted to the hospital, all for non-cardiovascular causes. CONCLUSIONS: During the first 3 months of TZB treatment none of the pts presented overt heart failure or significant LVEF deterioration. A significant reduction in the E/e' ratio was detected, but neither the loading parameters nor LVEF changed significantly .
Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Anticorpos Monoclonais Humanizados/efeitos adversos , Antineoplásicos/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Insuficiência Cardíaca/induzido quimicamente , Ecocardiografia Doppler/métodos , Insuficiência Cardíaca , Estudos Prospectivos , /metabolismo , Volume Sistólico/efeitos dos fármacos , Resultado do Tratamento , Função Ventricular Esquerda/efeitos dos fármacosAssuntos
Idoso , Humanos , Masculino , Angiografia Coronária , Vasoespasmo Coronário , Cardiomiopatia de Takotsubo , HemodinâmicaRESUMO
BACKGROUND: Trastuzumab (TZB) is a recombinant humanized monoclonal antibody, used for the treatment of HER2-positive breast cancer, with recognized associated-cardiotoxicity. The methods for its early sub-clinical detection are not well defined. OBJECTIVE: To evaluate TZB-induced cardiotoxicity in patients (pts) with breast cancer followed for a 3-month period of treatment. METHODS: Prospective study of consecutive pts treated with TZB for advanced HER2-positive breast cancer enrolled between May-September/2010. A comparison of clinical, laboratory and echocardiographic data, prior to and at the 3rd month after starting TZB was performed. Left ventricular systolic function deterioration (Cardiac Review and Evaluation Committee criteria) and diastolic function (American Society of Echocardiography classification) were studied. RESULTS: Data were available for 51 women, mean age = 55.4 ± 14.0y. At the 3rd month, no patient had symptomatic heart failure. Left ventricular ejection fraction (LVEF) did not differ at 3 months (69.3 ± 7.4 vs. 67.1 ± 6.5%, p > 0.05), decreasing in 57.9% pts (only one to LVEF < 55%). There was a significant increase in the E/e' ratio (3.9 ± 0.8 vs. 8.0 ± 1.9, p < 0,001) due to an e' velocity reduction (0.19 ± 0.02 vs. 0.10 ± 0.03, p < 0.001). Other diastolic parameters remained unchanged. Both the left atrial and the left ventricular volumes remained unchanged. N-terminal pro-B type natriuretic peptide levels did not increase. During the follow up period two pts died and two were admitted to the hospital, all for non-cardiovascular causes. CONCLUSIONS: During the first 3 months of TZB treatment none of the pts presented overt heart failure or significant LVEF deterioration. A significant reduction in the E/e' ratio was detected, but neither the loading parameters nor LVEF changed significantly .